Mesenchymal Stem Cells And Differentiated Insulin Producing Cells Are New Horizons For Pancreatic Regeneration In Type I Diabetes Mellitus | 99207
Journal of Gastrointestinal & Digestive System
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Background: Diabetes mellitus has become the third human killer following cancer and cardiovascular disease. Millions of
patients, often children, suffer from type 1 diabetes (T1D). Stem cells created hopes to regenerate damaged body tissues and
restore their function.
Aim: This work aimed at clarifying and comparing the therapeutic potential of differentiated and non-differentiated
mesenchymal stem cells (MSCs) as a new line of therapy for T1D.
Methods: 40 female albino rats divided into Group I (control): 10 rats and group II (diabetic), III and IV, 10 rats in each, were
injected with streptozotocin (50mg/kg body weight). Group III (MSCs) were transplanted with bone marrow derived MSCs
from male rats and group IV (IPCs) with differentiated insulin producing cells. Blood and pancreatic tissue samples were taken
from all rats for biochemical and histological studies.
Results: MSCs reduced hyperglycemia in diabetic rats on day 15 while IPCs normalizes blood glucose level on day 7. Histological
and morphometric analysis of pancreas of experimental diabetic rats showed improvement in MSCs-treated group but in
IPCs-treated group, ?-cells insulin immunoreactions were obviously returned to normal, with normal distribution of ?-cells
in the centre and other cells at the periphery. Meanwhile, most of the pathological lesions were still detected in diabetic rats.
Conclusion: MSCs transplantation can reduce blood glucose level in recipient diabetic rats. IPCs initiate endogenous pancreatic
regeneration by neogenesis of islets. IPCs are better than MSCs in regeneration of ?-cells. So, IPCs therapy can be considered
clinically to offer a hope for patients suffering from T1D.
Nermin Raafat completed my MD-PhD at age of 36 from Basel University, Switzerland. I'm an assistant professor of Medical Biochemistry and Molecular Biology at Zagazig University School of Medicine, Egypt. I'm the director of Molecular Biology and Cell Culture Lab at the department, Head of Cell culture unit of Scientific and Medical Research centre, the director of Project Management Unit, the admin of Institutional Review Board and a member of Scientific research council at Zagazig University School of Medicine, Egypt. I've published more than 30 papers in reputed journals and participated in more than 30 in ternational conferences.